Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the combination of the pivotal phase 2 study, HORIZON and phase 3 study,…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides explains the significance of the latest data findings from the O-12-M1 clinical trial recently…
Jakob Lindberg, CEO of Oncopeptides @oncopeptides discusses the 5 clinical trials for the treatment of relapsed/refractory multiple myeloma: O-12-M1, Horizon,…
Ron Peck, MD, CMO of Arvinas @Arvinas on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic…
Ron Peck, MD, CMO of Arvinas @Arvinas answers common questions on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat…
Ron Peck, MD, CMO of Arvinas @Arvinas discusses the initial safety and PK data on an orally-active proteolysis targeting chimera (PROTAC) molecule…
Ron Peck, MD, CMO of Arvinas @Arvinas discusses an orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic…
Dr. Mark Tuthill, MD of University of Oxford explains the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy…
Dr. Mark Tuthill, MD of University of Oxford answers the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy:…
Dr. Mark Tuthill, MD of University of Oxford discusses the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy.…
Dr. James Bates, MD @JamesBatesMD of University of Florida @UF answers is this reflective of long term techniques on long…
Dr. James Bates, MD @JamesBatesMD of University of Florida @UF discusses long term outcomes in 10-year survivors of early-stage hodgkin…
Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small…
Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small…
Rosario Campelo, MD of University Hospital of A Coruña discusses ALUNBRIG (brigatinib) as a first-line treatment for ALK + non-small…
Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia.…
Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia.…
Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia.…
John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed…
Philadelphia, PA (April 7, 2020) – Oncoceutics, Inc., a clinical-stage drug discovery and development company with a novel class of…
Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews explains the phase II trial in effective immunotherapy with markers of immune activation…
Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews answers if the markers are predictive of outcomes on immunotherapy with markers of…
Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews discusses effective immunotherapy with markers of immune activation in metastatic prostate cancer. While…
David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai: how information is generated. A leading molecular science…
David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai. A leading molecular science innovator focused on delivering…
A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI…
Dr. Giuseppe Curigliano, MD, PhD @curijoey of University of Milan on patient care and COVID-19 containment in Italy. Read here:Â https://dailynews.ascopubs.org/do/10.1200/ADN.20.200068/full/?cid=DM4782&bid=40579286
Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth discusses the patients with newly diagnosed glioblastoma, initial experience with scalp saving…
Dr. Adil Akhtar, MD of Karmanos Cancer Institute discusses important points to note on the rapidly changing COVID-19 for cancer…
Dr. Adil Akhtar, MD of Karmanos Cancer Institute discusses COVID-19 possibly delaying cancer treatments because during treatment, patients may be…
Wenyin Shi, MD of Jefferson Health @TJUHospital #JeffersonHealth answers common questions asked on the patients with newly diagnosed glioblastoma, initial…
What is KEYNOTE-189? Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses important points to note in NSCLC. In…
Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer answers common questions on KEYNOTE-189. If the PD-L1 expression is less…
Philadelphia, PA (April 1, 2020) – Oncoceutics, Inc., announced that it was informed by its Japanese licensee, Ohara Pharmaceutical Co.,…
Philadelphia, PA (March 26, 2020) – Oncoceutics, Inc. announced that the Chinese National Intellectual Property Administration (CNIPA) has issued a…
Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses an updated analysis on KEYNOTE-189: pembrolizumab or placebo plus pemetrexed…
Amy Moore, PhD @amoorephd of GO2 Foundation of Lung Cancer @GO2Foundation explains that COVID-19 infection rate is doubled for cancer…
Heinz-Josef Lenz, MD Professor of Medicine and Preventive Medicine Associate Director, Clinical Sciences J Terrence Lanni Chair in Cancer Research…
Amy Moore, PhD @amoorephd of GO2 Foundation of Lung Cancer @GO2Foundation discusses the intersection of COVID-19 and lung cancer patients.…
Tanya Dorff, MD Associate Clinical Professor of MedicineHead of Genitourinary Cancer Program City of Hope discusses Genitourinary Cancers:Evolving Practices and…
Zev A. Wainberg, MD Associate Professor Of Medicine Co-Director GI Oncology Program David Geffen School of Medicine at UCLA gives…
Nick McAndrew, MD MSCE Clinical Instructor Division of Hematology / Oncology UCLA David Geffen School of Medicine discusses updates in…
Herbert Eradat, MD, MS @dgsomucla Associate Clinical Professor UCLE Lymphoma Program UCLA BMT & CAR-T Cell Program, David Geffen School…
Nagi El Saghir, MD @NagiSaghir of American University of Beirut Medical Center @AUBMC_Official discusses how to care for oncology patients…
Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA answers common questions on the characteristics and trends in adult acute…
Tamer Othman, MD @tamerothman10 of Harbor-UCLA Medical Center @HarborUCLA discusses the characteristics and trends in adult acute lymphoblastic leukemia. The…
Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer explains CAR-T treatment in hematological malignancies affecting clinicians and moving forward with the…
Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer answers commong questions on CAR-T treatment in hematological malignancies and the toxicities used.…
Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer discusses CAR-T treatment in hematological malignancies. Â Chemeric antigen receptor (CAR)-T-cell therapy has…
This quick tutorial shows in detail how to create an account on OncologyTube.com and how to upload a video. The…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director, Experimental Therapeutics Cedars Sinai Foundation discusses the Multi-Modality Management of Melanoma in the…
Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients…
Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients…
Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients…
Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews addresses how the randomized phase IIB trial of proton beam therapy versus intensity-modulated…
Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews answers if this can be extended to the community on the randomized phase…
Company completes CLIA Validation of DetermaIOâ„¢, previously the Insight Genetics IM Score Test, establishing the test as a reliable and robust…
Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews discusses the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation…
Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses the effects of cardiac toxicities in the phase 3 CLEOPATRA study…
Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer answers common questions in the phase 3 CLEOPATRA study in HER2 metastatic…
Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses findings in the phase 3 CLEOPATRA study in HER2 metastatic breast…
Experience with COVID-19 in Wuhan, China shows up to half of patients present with a digestive symptom as chief complaint…
Experts from Seattle Cancer Care Alliance share lessons learned from early experiences treating people with cancer during COVID-19 outbreak via…
Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers if this will affect clinicians and treatment for progression-free…
Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers what type of TP53 mutations benefited from this for…
Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO answers questions on immunotherapy for a drug used for breast…
Cherie-Ann O. Nathan, MD of LSU Health Shreveport @LSUHS @LSUHealthNO discusses a drug used for breast and kidney cancer may…
 VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously…
Allison King, MD of Washington University School of Medicine @WUSTLmed answers the gender disparities in hematology research: how this will affect clinicians…
Allison King, MD of Washington University School of Medicine @WUSTLmed discusses the results on gender disparities in hematology research success. ______________ Hematologists…
Allison King, MD of Washington University School of Medicine @WUSTLmed discusses the study on gender disparities in hematology research success. ______________…
Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed…
Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed…
Tom Davis, MD @ThomasADavisMD of @GenoceaBio discusses the advancing part B of GEN-009 phase 1/2a trial with first patient dosed…
Thomas Moran, PhD of @MountSinaiNYC @IcahnMountSinai discusses advance novel biotherapies for treating cancer and coronavirus COVID-19 and new projects that…
Thomas Moran, PhD of @MountSinaiNYC @IcahnMountSinai discusses advance novel biotherapies for treating cancer and coronavirus COVID-19. #cancer #biotherapies #treatment #covid19…
Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to…
Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to…
JNJ-6372, a dual-targeting EGFR-MET bispecific antibody, is being investigated for adults with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion…
Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to…
Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell answers a way to enhance the potency of blood-forming stem cells: how does…
Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell answers a way to enhance the potency of blood-forming stem cells, potentially opening…
Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell discusses a way to enhance the potency of blood-forming stem cells, potentially opening…
Mount Sinai researchers have discovered a way to enhance the potency of blood-forming stem cells, potentially opening the door to…
Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research…
The standard of care for small-cell lung cancer (SCLC) had been unchanged for over 20 years, with platinum-based chemotherapy being…
Neal Shore, MD of Carolina Urologic Research Center @AtlanticUrology explains the randomized phase II study of sipuleucel-T with or without radium-223: how…
Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223…
Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223…
Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO…
Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO…
Neal Shore, MD of Carolina Urologic Research Center explains cerebral blood flow (CBF) in regions relevant to cognitive function with…
– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients…
NCCN celebrates 25th anniversary year; shares updates from oncology experts on leading-edge cancer management practices during NCCN 2020 Annual Conference in…
Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient in Japan has initiated treatment…
While radiation is successfully used to treat breast cancer by killing cancer cells, inflammation caused as a side-effect of radiation…
Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder…
Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder…
Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder…
Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial – – Astellas Pharma Inc. (TSE: 4503,…
Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: the importance of mutation testing.
Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: how this affects clinicians, patients and treatment today.
Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: does FGFR targeted therapy work better than an immune…
Arlene Siefker-Radtke, MD of @MDAndersonNews discusses the phase 1b/2 NORSE study on the treatment of metastatic urothelial carcinoma in patients…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses fundamental mechanism for other clinical outcomes and phenotypes. ___________ In a new Cleveland…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses HSD3B1(1245C) – how this affects clinicians and treatment today. _________ In a…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic answers common questions between genetic variant and poor outcomes in men with metastatic…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses a link between genetic variant and poor outcomes in men with metastatic…
Caregiving responsibilities found to negatively affect academic productivity, primarily for men Hematologists who complete a mentored training program experience greater…
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer explains how oral therapies will impact the treatment…
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer considers what we have learned from understanding real-world…
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer elaborates on the role of venetoclax in treatment…
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center,…
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center,…
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center,…
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center,…
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, discusses the most…
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, tells us about…
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, shares the design…
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his opinion on zanubrutinib as compared to other second-generation…
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his impression of the pivotal clinical data that lead…
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews speculates on therapies for front-line and relapsed mantle cell lymphoma.
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews elaborates on the ZUMA-2 trial investigating anti-CD19 CAR-T cell therapy…
Peter M. Voorhees, MD @LevineCancer shares the current thinking regarding treatment algorithms in relapsed/refractory multiple myeloma.
Peter M. Voorhees, MD @LevineCancer explains how daratumumab is changing the way multiple myeloma (MM) patients are treated today.
Peter M. Voorhees, MD @LevineCancer summarizes the design and outcomes of the Phase 2 Griffin study in newly diagnosed multiple…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, tells us about the results of…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, considers the ideal patient profile for…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, offers her impression of the Phase…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, offers opinion on how physicians should…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, tells us about Veneto-STOP study presented…
Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, regarding the ideal patient profile in relapsed or…
Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, offers his impression of the pivotal clinical data…
Max Topp, MD, Professor and Head of Hematology, University Hospital of Wuerzburg Germany, on the development of a new risk…
Max Topp, MD, Professor and Head of Hematology, University Hospital of Wuerzburg Germany, shares the long-term results of the ZUMA-1…
– ALUNBRIG has Potential to Expand its Indication in ALK+ Metastatic Non-Small Cell Lung Cancer – – Prescription Drug User…
 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced its plan to initiate a Phase…
Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impression of the pivotal clinical data that lead…
Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impressions of the Phase 2 CAPTIVATE study investigating…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber shares thoughts on current treatment strategies for elderly acute myeloid leukemia…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber elaborates on prognostic factors and the relationship to outcomes in acute…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber offers his impression of the landscape for FLT3 inhibition in acute…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber provides opinion on whether all acute myeloid leukemia (AML) patients should…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber describes the landscape of mutations and targeted therapy in acute myeloid…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer discusses the prognostic factors in acute myeloid leukemia…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer offers her overall impression on the changing FLT3…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether there are emerging mutations in FLT3…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether all acute myeloid leukemia (AML) patients…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine @UCSFMedicine tells us about the outcomes of the Phase…
Two-drug combination effective in lab studies against aggressive prostate tumors Research team identifies new approach to treating prostate cancer Metabolic…
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates…
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, considers…
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, offers…
John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, considers whether minimal…
John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, tells us about…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, on whether medical oncologists are adopting…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, offers opinion on the most promising…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, regarding the role of proteasome inhibitors…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, explains the role of daratumumab as…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer discusses the data investigating iberdomide presented at ASH…
Adult cancer patients reported better physical and social function after undergoing CAR-T therapy Adult lymphoma patients whose disease was effectively…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer provides opinion on the role of BCMA CAR-T…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer considers the Phase 3 ICARIA-MM study investigating isatuximab…
Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer tells us about the design and outcomes of…
Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope considers…
Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope discusses…
Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope discusses…
Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope shares…
Moleculin Biotech, Inc., (Nasdaq:Â MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates…
Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses prognostic…
Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses some…
Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, elaborates on…
Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering offers opinion on whether there is sufficient evidence to…
Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering shares clinical outcomes from the investigation of the vemurafenib…
Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society,…
Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society,…
Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society,…
Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society,…
Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer…
In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with…
Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer…
Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer…
Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai provides perspective on how oral therapies will impact…
Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai elaborates on the current approaches to treating elderly…
Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai offers opinion on how the treatment of myelodysplastic…
First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the…
Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, discusses if there is an…
Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, tells us about the outcomes…
Pancreatic cancer has one of the worst survival rates among cancers. Patients can expect as low as a 9% chance to…
James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes…
James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes…
James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes…
James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, shares his…
Longeveron LLC, a leading developer of adult stem cell technologies for aging-related and life-threatening conditions, announced today that it has…
John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai discusses whether molecular analysis is appropriate and…
John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai tells us about his approach to the…
John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai shares outcomes from the MANIFEST study investigating…
Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine compares the effectiveness of rasburicase versus allopurinol in cancer patients with hyperuricemia.
Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine describes those patient types more suited for treatment with rasburicase versus allopurinol.
Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine discusses the advantages of rasburicase compared to allopurinol in managing tumor lysis…
Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine considers whether there are particular patient types more prone to tumor lysis…
Immunomedics has developed an antibody drug conjugate (ADC) called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to triple negative breast…
Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC explains how JNJ-4528 differs from other CAR-T products.
Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC tells us about the outcomes of the CARTITUDE-1 study…
Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC on how CAR-T cell therapy plays a role in…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA offers opinion on how physicians should be thinking…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers whether minimal residual disease (MRD) is a…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA tells us about the four-year update on the…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers the ideal patient profile for zanubrutinib in…
Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center…
Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center…
Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center…
Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center…
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, provides insight on the real-world evidence presented at ASH 2019 regarding…
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of…
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma.
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, discusses how physicians should be thinking about the use of BTK…
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the Phase 3 Dreamm-3 study,…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope describes the results of the Phase 1 study…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the outcomes of the CARTITUDE-1…
Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope elaborates on BCMA-directed strategies for multiple myeloma patients.
GRACE is very excited to bring to you more videos from our program, Supportive Care in Cancer Treatment.Arjun Gupta, MD…
Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video Dr. Gupta…
Source: https://www.spreaker.com/user/cancergrace/supportive-care-5-chemobrain-podcast We are very excited to bring to you this new program on supportive care in cancer treatment. In…
Source: https://www.spreaker.com/user/cancergrace/supportive-care-6-pert Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video,…
Michael Jain, MD Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews offers his opinion on off-the-shelf…
Michael Jain, MD Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews tells us about the outcomes…
Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews tells us about the outcomes of the US…
Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews discusses how population-based outcomes in…
Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews offers perspective on the latest…
Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM shares the…
Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM explains the…
Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM describes the…
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, offers insight of the Phase 3 ICARIA-MM trial investigating…
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, tells us about the design and outcomes of the…
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, explains how novel combination treatment options and sequencing strategies…
Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, elaborates on the role of stem cell transplantation in…
Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC considers whether off-the-shelf CAR-T cell therapies are becoming a…
Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC offers impressions of the TRANSCEND-CLL-004 data investigating the use…
Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC discusses the three-year survival analysis of the ZUMA-1 study…
Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC tells us about the results of the ZUMA-2 study…
Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth explains how oncologists are using RWE today.
Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth provides examples of how real-world evidence (RWE) has impacted…
Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth defines real-world evidence (RWE) and explains how it can…
James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the future of off-the-shelf CAR-T cell therapy.
James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses off the-shelf CAR natural killer (CAR NK)…
James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, offers his insight on the recent data investigating…
James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the integration of stem cell transplantation into…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews provides insight on current treatment strategies for…